Mer­ck scores pri­or­i­ty re­view Keytru­da in squa­mous NSCLC; Syn­thet­ic Ge­nomics spin­out SGI-DNA gets new CEO

7 years ago
News Briefing

Hong Kong ex­change picks up steam with two biotech IPOs from In­novent, Mi­cuRx

7 years ago
Financing
China

No­var­tis dumps world­wide rights to an Aveo drug, and the lit­tle biotech is not hap­py with them

7 years ago
R&D

Re­gen­eron, Sanofi show re­straint on Dupix­ent price hike, but Pfiz­er’s hard charge con­tin­ues to spur calls for a ...

7 years ago
Bioregnum
Opinion

Catal­ent inks $133M deal to buy Ju­niper Phar­ma­ceu­ti­cals, adding UK de­vel­op­ment ser­vices

7 years ago
Deals
Outsourcing

Is Mar­tin Shkre­li blog­ging from prison?

7 years ago
People

'Bio­hack­er' Tray­wick ac­ci­den­tal­ly drowned, of­fi­cial con­firms

7 years ago
People

What's BIO and PhRMA do­ing to ad­dress sex­u­al ha­rass­ment? Sen­a­tor Mur­ray wants to know

7 years ago
Pharma

Sanofi gets se­ri­ous in Chi­na with plans to hire 300 for $76M R&D site in Cheng­du

7 years ago
R&D
China

MiMedx shares swoon as purge claims CEO; Those big cuts in drug prices you heard about? Pfiz­er has oth­er ideas

7 years ago
News Briefing

Af­ter clos­ing the gap on new hires, FDA could face an ex­o­dus of top reg­u­la­tors

7 years ago
R&D
Pharma

RIP XTu­it: Great brains, hot tar­get and vet CEO Deb­o­rah Dun­sire in charge couldn’t stop this biotech from go­ing ...

7 years ago
Financing
Startups

With $100M in fresh back­ing and a new TCR ini­tia­tive, Athenex launch­es Chi­na JV

7 years ago
Financing

Roche vaults in­to lead in front­line triple neg­a­tive breast can­cer as Tecen­triq/Abrax­ane com­bo aces pro­gres­sion-free ...

7 years ago
R&D

GSK-backed Liq­uidia takes a seat at the IPO ta­ble, look­ing for a $57.5M stake to take on Unit­ed Ther­a­peu­tics

7 years ago
Financing

For­get the biotech mega-round. Try the $200M-plus Chi­na 'ul­tra' on for size

7 years ago
Financing
China

Af­ter biotech im­plo­sions, ex-Mil­len­ni­um chief Deb­o­rah Dun­sire is tak­ing the helm at Lund­beck

7 years ago
People

No­var­tis to spin off Al­con eye care unit, buy back $5B in stock; Ri­val CAR-Ts from No­var­tis and Gilead get thumbs up ...

7 years ago
News Briefing

An­drew Rit­ter gath­ers the reins as his com­pa­ny preps PhI­II; Sol­id Bio co-founder Gi­lad Hay­eem re­tires

7 years ago
Peer Review

Ac­ne was a bust, but ex­ces­sive sweat­ing scores FDA OK for Der­mi­ra — shares climb

7 years ago
Pharma

How does the first half of 2018 mea­sure up against the last 7 years for biotech IPOs?

7 years ago
Financing
Pharma

Three years lat­er the FDA fi­nal­ly lifts its hold on Ap­tose drug, set­ting the stage for a re­turn to PhIb

7 years ago
Pharma

Bat­tered Gem­phire shares soar on new triglyc­eride da­ta, but there’s a lot left to prove

7 years ago
R&D

Fi­nal­ly, Cel­gene wins. Ane­mia drug lus­pa­ter­cept — part­nered with Ac­celeron — scores in PhI­II tri­al

7 years ago
R&D
First page Previous page 1015101610171018101910201021 Next page Last page
A service from the Financial Times